The Effects of Resveratrol on Inflammation and Oxidative Stress in a Rat Model of Chronic Obstructive Pulmonary Disease

Abstract

Oxidative stress and inflammation are hypothesized to contribute to the pathogenesis of chronic obstructive pulmonary disease (COPD). Resveratrol (trans-3,5,4′-trihydroxystilbene) is known for its antioxidant and anti-inflammatory properties. The study aimed to investigate the effects of resveratrol in a rat model with COPD on the regulation of oxidative stress and inflammation via the activation of Sirtuin1 (SIRTl) and proliferator-activated receptor-γ coactivator-1α (PGC-1α). Thirty Wistar rats were randomly divided into three groups: control group, COPD group and resveratrol intervention group. The COPD model was established by instilling with lipopolysaccharide (LPS) and challenging with cigarette smoke (CS). The levels of interleukin-6 (IL-6) and interleukin-8 (IL-8) in serum were measured. The levels of malondialdehyde (MDA) and the activity of superoxide dismutase (SOD) were measured. The expression levels of SIRT1 and PGC-1α in the lung tissues were examined by immunohistochemistry as well as real-time reverse transcriptase polymerase chain reaction (real-time RT-PCR) and western blotting analysis. After the treatment with resveratrol (50 mg/kg), compared with the COPD group, alleviation of inflammation and reconstruction in the small airways of the lungs were seen. Resveratrol might be correlated not only with the lower level of MDA and the higher activity of SOD, but also with the upregulation of SIRT1 and PGC-1α expression. Resveratrol treatment decreased serum levels of IL-6 and IL-8. Our findings indicate that resveratrol had a therapeutic effect in our rat COPD model, which is related to the inhibition of oxidative stress and inflammatory response. The mechanism may be related to the activation and upgrading of the SIRT1/PGC-1α signaling pathways. Thus resveratrol might be a therapeutic modality in COPD.

Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies

“…Along with this, resveratrol treatment also attenuated the cigarette smokeinduced fibrotic response and mucus hypersecretion in the lungs (Andrews et al, 2016). A recent study in rats also confirmed the efficacy of resveratrol in COPD, and that the beneficial effect of resveratrol may be exerted via the SIRT1 and PGC-1α axis (Wang, Li, Li, Miao, & Xiao, 2017). Resveratrol therapy is currently in phase 3 clinical trials for use in COPD patients (CARMENS-trial; ClinicalTrials.gov Identifier NCT02245932).…”

Health benefits of resveratrol administration

“…Moreover, resveratrol protects the spinal cord from ischemic damage in rats by reducing plasma levels of nitrite, AOPP and MDA, and increasing the enzymatic activity of SOD and CAT (Fu et al, 2018). Resveratrol also attenuates oxidative stress in rats with experimental periodontitis (Corrêa et al, 2018), induced early Alzheimer's disease (Lin et al, 2018) and chronic obstructive pulmonary disease (Wang et al, 2017).…”

Resveratrol Mediates Mechanical Allodynia Through Modulating Inflammatory Response via the TREM2-autophagy Axis in SNI Rat Model

“…Previous studies have shown that resveratrol has neuroprotective properties in NeuP, AD, and PD. It has been demonstrated that resveratrol attenuated in ammation by inhibiting the pro-in ammatory cytokine secretion in the obese model and cirrhotic model [35][36][37]. Administration of resveratrol elicits neuroprotective function via suppressing glial activation and decreasing the secretion of proin ammatory cytokines in PD mice [14,38].…”